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l Introduction
The best treatmentof respiratory distress syndrome (RDS) is preventive. The occurrence of the syndrome can be lessened by the antenatal assessment of fetal lung maturity, thus leading to an improved selection of pregnancies for induction. Parallel to this passive management many efforts have been made to accelerate the physiological synthesis of pulmonary surfactant. LIGGINS and Howrn [8] were the flrst to demonstrate a decrease in RDS in premature infants by the antenatal administration of Be tarne thasone to the mother. Since then other corticosteroids and other routes of administration have also come into use [2, 17] . Due to the theory that the increase in the phospholipid component of surfactant may be mediated by thyroxine, its use for accelerating fetal lung maturity has been tested. Experimental studies in rats and rabbits have demonstrated the effect of thyroxine in accelerating fetal lung maturity [11, 18] .' In humans thyroxine has been injected into the amniotic sac for other purposes 12-24 hours prior to delivery without any early deleterious effect to mother or newborn [4] . These observations provided the basis for using this hormone in pregnant women in order to accelerate fetal lung maturity. Reports in the literature have also demonstrated the link between low thyroxine levels and an increased incidence of RDS [3, 15] . Our preliminary report showed promising results using thyroxine to accelerate human fetal lung maturity [9] . The results presented here are those of an extended and controlled study. 0300-5577/79/0007-0161$02.00
Curriculum vitae
The object of this study was to ascertain the effect of thyroxine administration on the biochemical and clinical maturation of fetal lung. Thyroid hormone was injected intra-amniotically in 16 high risk pregnancies between 29-34 weeks. The incidence of RDS and the fetal lung maturity were then examined and compared to a control group. Fetal lung maturity was determined in the following study by a new method based on a fluoroscence polarization technique [14] .
Materials and methods
The physical basis of this new method of assessment of fetal lung maturity stems from the empi-'rical relation between the viscosity and surface tension of fluids. Both of these physical parameters are determined by the intermolecular forces of the fluid and are therefore interrelated. The correlation between these parameters implies that the surface tension of the pulmonary surfactant can be translated into an intrinsic viscosity parameter which may be expressed in terms of microviscosity [13] . The efficient technique for determination of lipid microviscosity is by fluorescence depolarization of a hydrocarbon probe 1,6-diphenyl 1,3,5-hexatriene (DPH) embedded in the core of the System. The detected degree of fluorescence polarization P is directly related to the totational motion of the probe and therefore to the microviscosity of the hydrocarbon region of the lipid assembly. Measurements are carried out with a highly accurate microviscosimeter now termed FELMA* [14] .
Determination of P
One ml of amniotic fluid centriftige d at 1000 PRM for 10 minutes is mixed with four ml of DPH dispersion and is incubated at 37°C forSOminutes. The sample is then allowed to cool to room temperature and is ready for determination of the fluoroscent polarization P. Fluorescence polarization P is not a linear parameter, therefore we have tried in aprevious study to translate it into viscosity units e = Poise.
* FELMA -Fetal lung maturity analyzer, Elscint Ltd., Haifa, Israel.
In the present study we are using again the P value for it is already well accepted in several centers and practically, P values obtained from amniotic fluid samples are all within the linear zone of the scale.
In the first publication using that method [14] fetal lung maturity was defined äs a P value of 0.310 or below. Since then with some experience of the method P -0.315 (0.312 ± 0.005) is taken äs the upper limit of maturity. All amniotic fluid sainples were obtained by transabdominal amniocentesis. Aiiy sample contaminated by blood or meconiüm was discounted.
Selection of patients
183 amniotic fluid samples were obtained in order to determine the lung maturity (P) at different stages of pregnancy. This series comprises pathological pregnancies (e.g. premature contractions, pre-eclamptic toxemia, rhesus incompatibility, diabetes, placental insufficiency and placenta praevia) in which premature delivery was inevitable or necessary, and also normal pregnancies examined prior to elective caesarean section. The study was carried out in two stages. In the first stage the microviscosity (P) of 104 pathological pregnancies was measured in order to evaluate the advisability of early delivery. When the data from this group was found to be reliable by clinical confirmation, thyroxin was administered to 16 other patients who were between 29-34 weeks of pregnancy. The 104 patients of the first stage of this study were therefore regarded äs a control group äs compared to the second group of 16 patients who received treatment.
4.1 Üntreated group -138 amniotic fluid samples were obtained from 104untreated cases. The results of these samples were used in order to plot the P value curve äs a function of gestational age. 73 out of these samples were obtained once from singleton pregnancies. 25 were obtained twice from singleton pregnancies 3 were obtained three times from singleton pregnancies and 3 samples were obtained once each from multiple pregnancies (one sample per sac 4.4 The criteria and conditions used in the selection of patients were:
l.The thyroxine injection and date of delivery, both occurred between 29-34 weeks when there was no doubt äs to gestational age. 2. The P value was determined before and after the administration of T 4 in order to ascertain the effect of T 4 on this parameter. 3. Clinical follow-up was carefully recorded during the neonatal period. 4. A unified approach to treatment of pathological conditions was strived for both the experimental and the untreated groups. 5. No additional treatment (e.g. steroids) was administered to either groups for the acceleration of fetal lung maturity. 4*5 Multiple pregnancies: In the entire series there were 5 cases of multiple pregnancy. 3 sets of twins in the control group l set of twins in the experimental group and l set of triplets in the experimental groups.
In the cases of multiple pregnancy in order to ensure that we were handling the individual sacs, we used ultrasonography to ascertain the position of the fetuses and dye* was added to differentiate the sacs from one another. The technique in the use of the dye was to inject it into first sac after amniocentesis had been performed in that sac, so that when the amniocentesis was performed in the second sac, the colourless fluid withdrawn was a proof of puncture of a different sac.
* Indigocarmine 0.4%
In the cases of triplets, dye was injected also into the second sac (following the amniocentesis in that sac). In those cases in which a repeat amniocentesis was performed, the above procedure was carried out, but a radiopaque medium** was used in place of regulär dye. The amniotic fluid samples were placed in tubes which were then X-rayed in vitro.
4.6 Thyroxine administration: Prior to each injection of thyroxine, 20 ml of clear fluid were obtained by amniocentesis. 250 § of Levothyroxine*** were then injected through the same needle. In all cases a recording of the fetal heart beats was made for some hours following the in-• jection in Order to diagnose fetal tachycardia or any other kinds of arrhythmia äs a possible sign ofT 4 overdose. The only criterion for the administration of a second T 4 injection was the P value of the previous amniocentesis.
RDS was defined äs follows:
1. Grunting 2. Sternal and intercostal retractions 3. An X-ray picture of reticular granularity and an air bronchogram. 4. Tachypnea 5. Cyanosis in room air 6. Alae nasi movements A diagnosis was not regarded äs certain unless at least criteria, l, 2 and 3 were present.
Results
The effect of intra-amniotic T 4 injection on the dynamics of fetal lung ripening in 16 cases is shown in Fig. 1 . In 14 cases the fetal lungs matured (P value < 0.315), in 6 bases after one injection and in other cases after two or more injections. One case of the 14 was already mature when the first amniocentesis was performed. In two cases maturity was not achieved, though in one of them ** Diatrizoate sod. 50% (Triognost) *** Synthroid (Flint Laboratories, USA).
the Fluorescence polarization value "P" was borderline(P = 0.317). The mean P value after thyroxine administration were compared to the mean P values in the control group where P values of amniotic fluid samples were determined but T 4 was not given. (Fig. 2) . No statistical evaluation was made in experimental sub-group I (29-30 weeks) äs there were too few cases. In subgroup II (31-32 weeks) there was a statistically significant difference (P < 0.005). The clinical details of the 16 patients are shown in Tab. II. Each of the fetuses was delivered before 34 weeks. Nine were delivered by caesarean section for various indications, and seven vaginally, of which four with pathological presentations. The birth weights of the premature infants were between 900-2900 grams and RDS was seen in only one infant. 21 out of the 38 pregnant women who comprise the control group gave birth beyond the 34 th week of pregnancy, in four of these newborns RDS developed.
Discussion
One of the methods avaüable to prevent intrauterine death in high risk pregnancies is to induce labor prematurely. The dilemma faced when deciding upon the management, however, is in exposing the premature infant n to RDS (especially under 34 weeks). The use of pharmacological agents for accelerating fetal lung maturity is an important approach demanding further investigation and development. Corticosteroids have proved to be an acceptable method for accelerating lung maturity. In cases of high risk pregnancy, however, such äs toxemia and placental insufficiency, where acceleration of maturity is most needed, there is a relative contraindication to giving steroids [8] . The incidence' of intra-ventricular cerebral hemorrhage has been reported to be higher in RDS infants who have received steroids than in a control group [l, 16] . Therefore, the search for other modes of treatment is understandable. As far äs we know thyroxine has never been used to accelerating fetal lung maturity in the human. This in spite of encouraging results in animals [11, 18] , and the lack of early side effects to mother and infant reported by FISHER et al.
[4]. Since thyroxine does not cross the placenta in significant quality [6] it is necessary to inject it directly into the amniotic sac. The J. Perinat. Med. 7 (1979) fetus absorbs the hormone from the liquor äs if it had been injected intrafetally [12] . Whilst our interest in the human lies in the acceleration of lung maturity following administration of thyroxine to the fetus, note must be taken of the reported effects upon brain development following administration of T 4 to newborn rats [10] . Carefull follow-up on human newborns regarding some possible influence of T 4 on the central nervous System is being carried out. So far no abnormality has been noted. The dosage of 250 g was arrived at in a preliminary study carried out in our department [9] . This dose is thrice the daily production of T 4 and its possible effect on the treated fetus [7] . This study, being a retrospective one, requires careful evaluation to achieve statistical significance. Patients in this study were admitted only according to strict criteria previously described. In 28 high risk pregnancies or inevitable premature deliveries T 4 was injected into the amniotic sac. Only 16 cases fulfilled these criteria. All the other 12 cases were discounted because of the impossibility to fulfill either one or more of the mentioned above criteria and conditions used in the selection of patients. Eight of them were discounted because of the impossibility of reexamining the P value after treatment (either due to the Intervention of labor, or contamination of the sample with blood or meconium). One of these 12developedRDS.
In all 16 cases the P value feil after injection. 13 of these cases achieved maturity (P < 0.315) after one or more injection of T 4 . In one case (K.S.) P value was already mature spontaneously in the first amniocentesis. In another case (L.V.) the value reached the threshold of maturity and in a third case (K.N.) labor occurred one week after the first injection and 6 hours after the second of T 4 , when the P value was still 01350. Determination of fetal lung maturity with the Fetal Lung Maturity Analyzer "FELMA" enables us to observe the dynamics of surfactant production. We intend to publish in the near future, the results of studies performed by us from which we feel confident to conclude that the P value can be used äs a reliable indicator of fetal lung maturity. In these studies, over a period of three years, we analyzed several huiidreds of samptes with the microviscosimeter FELMA and compared these results with the L/S ratio, the "foam test" and the clinical outcome of the newborn. T 4 in itself does not interfere with the fluorescence polarization of the examined samples äs the P value of T 4 solution was measured and was found to be undetectable. In order to determine whether the change in P value was an expression of thyroxine treatment and not merely due to gestational age, we compared mean P values after a course of thyroxine treatment and mean P values in an untreated control group. The control group comprised the same pathological spectrum äs the test group. Treatment for the specific pathological state when indicated was identical in both groups of patients.
Because the test group was small it was divided into subgroups of 2 weeks and not into separate weeks. In the subgroup I (29-30 weeks) there were only 2 cases, therefore, it was impossible to carry out statistical analysis on them and they were not included in Fig. 2 .
As can be seen from the results in Fig. 2 there is a statistically significant difference in the mean results of the subgroup II (31-32 weeks) and III (33-34 weeks) and their respective control groups. It seems logical to explain these effects äs resulting from the action of T4 on surfactant synthesis. Thyroid hormones fundamental actions are not entirely understood. Although it requires up to several days before a major clinical effect with T 4 is manifest, in adults, it seems that T 4 can act solely without converting to T 3 [4], Hence it is not impossible to explain the somewhat fast biological effect of T 4 on few cases in the present study. The object of the study was to ascertain the effect of T 4 administration on the P value äs an expres-sion of fetal lung maturity. Thus it is clear why we discarded those cases in which we didn't have both a pre-and post treatment P value. As amniocentesis itself is an invasive procedure it was only carried out in high risk pregnancies when the Information gained justified the Intervention. Most of the patients in the control groups were examined before T 4 was in use and the relative contraindications to using steroids on those patients left them without specific treatment for accelerating fetal lung maturity. The only criterion for the readministration of T 4 in the experimental group was the P value of amniotic fluid sample obtained by a previous amniocentesis. It is to be noted that in no case was there any ' difference in fetal heart rate pattern before or after T 4 administration recorded. Table II shows that only l of the 16 cases (H.M.) developed RDS. This infant was delivered by Caesarean section at 30 weeks because of severe toxemia and acute fetal distress. After intensive treatment which included administration of Indomethacin in order to close the patent ductus arteriosus (according to FRIEDMAN et al. [5] ), the infant made an uneventful recovery. It is quite difficult to explain the incidental RDS in case No. 8 (H.M.) in spite of a mature P value (= 0.306). However, one cannot ignore the predisposing factors for RDS in this particular case such äs prematurity, severe perinatal asphyxia caused by the fulminant toxemia and the urgent caesarean section. In case No. 15 (K.N.) no RDS was developed although P value indicated immaturity of the fetal lungs (P = 0.350), in spite of previous T 4 injection. Keeping in mind the possibility of false negative and false positive rates of any method, it is not impossible to presume that antenatal evaluation of surfactant content in aanniotic fluid is not the single meansto predict the development of RDS post-natally. In the two cases of multiple pregnancy the development of fetal lung maturity, including the responsiveness of each fetus to the T 4 treatment was individual and independent. (Fig. 1) . This aspect of the study is at present being investigated by measuring serum T 4 and TSH levels at birth and during the first 24 hours.
Summary
In this study we set out to examine the effect of thyroxine injection intraamniotically on the acceleration of fetal lung maturity. 183 samples of amniotic fluid from pathological pregnancies were examined at different stages of pregnancy; to determine fetal lung maturity by the evaluation of "P" (a measurement dependent on micioviscosity) previously described. 16 cases between 29-34 weeks received intra-amniotic thyroxine in order to accelerate the development of fetal lung maturity. In all 16 cases there was a significant improvement in the degree of lung maturity. 14 newborns were definitely mature. The desired maturity was not achieved in only two cases. The results of these 16 cases were cotnpared to a control group (untreated) which were chosen because of an identical gestational age and the same types of pathology. There was a statistically significant difference in the pulmonary maturity value 'P* after use of thyroxine in comparison to the control groups.
In 15 of the 16 treated cases, there was no RDS (Respiratory Distress Syndrome), and this in spite of the fact that they were all born before 34 weeks of pregnancy, and nine of them by Caesarean Section. In view of these results it seems that thyroxine treatment is one of the most efficient methods of preventing RDS in high risk pregnancies in which there is an indication for early induction of labor.
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